DCX and Alzheimer disease: By increasing DCX expression, KBN2202 is expected to promote neurogenesis and may thereby counteract neurogenic deficits, which represent a hallmark of AD pathology—an outcome not addressed by current amyloid-targeting therapies such as monoclonal antibodies [11,44].